From Nvidia News: 2025-06-11 06:52:00

Leading global pharma company, Novo Nordisk, partners with Danish AI enterprises and startups to improve drug discovery and healthcare. NVIDIA collaborates with Novo Nordisk to accelerate drug discovery through AI use cases using the Gefion AI supercomputer. The companies aim to create customized AI models for early research and clinical development.

Novo Nordisk utilizes DCAI’s Gefion supercomputer powered by NVIDIA DGX SuperPOD to run drug discovery and agentic AI workloads. The collaboration will focus on AI research programs to predict cellular responses to drug candidates, design molecules with drug-like properties, and build biomedical language models. The goal is to aid scientists in developing new medicines faster and more efficiently.

DCAI owns and operates Gefion, Denmark’s flagship AI supercomputer, lowering the barrier for accessing advanced computing capabilities in healthcare and drug discovery. Multiple customers, including Danish startup Teton, are leveraging Gefion to accelerate the development of AI technologies for healthcare, such as real-time 3D digital twins in patient rooms. The aim is to improve patient care and reduce nurses’ workload burden.

Gefion will be used by pharma companies to accelerate drug discovery in neurological and psychiatric disorders. Danish health organizations will use the supercomputer to unite health data for national analysis, enabling researchers to access interconnected health data securely. This will facilitate the analysis of large datasets, early disease pattern identification, and personalized treatments.

NVIDIA founder and CEO Jensen Huang’s keynote at VivaTech discusses the collaboration between Novo Nordisk and Danish AI enterprises to advance drug discovery using AI technologies. The partnership aims to revolutionize pharmaceutical development by harnessing the full potential of AI. The use of advanced AI models and simulation technologies will enhance research and development processes in the healthcare industry.



Read more at Nvidia News: NVIDIA Partners With Novo Nordisk and DCAI to Advance Drug Discovery